Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun-Jul;22(3):642-50.

2014 Update of the drug resistance mutations in HIV-1

Annemarie M Wensing  1 , Vincent Calvez  2 , Huldrych F Günthard  3 , Victoria A Johnson  4 , Roger Paredes  5 , Deenan Pillay  6 , Robert W Shafer  7 , Douglas D Richman  8
Affiliations

2014 Update of the drug resistance mutations in HIV-1

Annemarie M Wensing et al. Top Antivir Med. 2014 Jun-Jul.

Abstract

This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013. The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir. With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.

PubMed Disclaimer

Conflict of interest statement

Financial affiliations in the past 12 months: The authors (listed alphabetically) disclose the following affiliations with commercial organizations that may have interests related to the content of this article: Dr Calvez has served on advisory boards for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Pfizer, Inc, Roche, and ViiV Healthcare. Dr Günthard has served as an advisor and/or consultant for Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Novartis, Pfizer, Inc, Roche, and Tibotec Therapeutics, with all compensation going to his institution, University Hospital of Zurich. He has received unrestricted research and educational grants to his institution from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck Sharp & Dohme, and Roche; has served on a data and safety monitoring board for Merck Sharp & Dohme; and has received travel grants from Bristol-Myers Squibb and Gilead Sciences, Inc. Dr Johnson has received research support from Abbott Molecular, Roche Molecular Diagnostics, and Siemens Healthcare Diagnostics, Inc. Dr Paredes has received research grants awarded to IrsiCaixa and Lluita Contra la SIDA Foundations from Gilead Sciences, Inc, and ViiV Healthcare. Dr Pillay has no relevant financial affiliations to disclose. Dr Richman has been a consultant to Bristol-Myers Squibb, Chimerix, Gen-Probe Inc, Gilead Sciences, Inc, Sirenas, Prism, and Monogram Biosciences, Inc. He owns stock from Chimerix. Dr Shafer has served as a consultant or advisor for Celera and has received grants from Bristol-Myers Squibb F. Hoffmann-La Roche, Ltd, Gilead Sciences, Inc, and Merck & Co, Inc. Dr Wensing has served on advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc; has received grants from Janssen Pharmaceuticals, Inc, and ViiV Healthcare; and has received travel, accommodation, or meeting expenses from Bristol-Myers Squibb and Virology Education.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Johnson VA, Calvez V, Gunthard HF, et al. Update of the Drug Resistance Mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):6-14. - PMC - PubMed
    1. Fourati S, Visseaux B, Armenia D, et al. Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1–infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. J Antimicrob Chemother. 2013;68(10):2199-2204. - PubMed
    1. Haddad M, Napolitano LA, Frantzell A, et al. Combinations of HIV-1 reverse transcriptase mutations L100I + K103N/S and L100I + K103R + V179D reduce susceptibility to rilpivirine [Abstract H-677]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 10-13, 2013; Denver,Colorado
    1. Picchio GR, Rimsky LT, Van E V, Haddad M, Napolitano LA, Vingerhoets J. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine. Antivir Ther. 2014;[Epub ahead of print]. - PubMed
    1. Malet I, Gimferrer AL, Artese A, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother. 2014;[Epub ahead of print]. - PubMed

Publication types

Substances